Propel Bio Management, LLC
CIK: 1969764
Holdings (29)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 13, 2026
- PAGP
PLAINS GP HOLDINGS LP-CL
$30.88M
1.27M sh16.16%+0.0% - ACHV
ACHIEVE LIFE SCIENCES INC
$26.34M
4.03M sh13.79%+6.5% - CORT
CORCEPT THERAPEUTICS INC
$11.87M
136,499 sh6.21%-7.7% - PHAT
PHATHOM PHARMACEUTICALS I
$11.4M
1.05M sh5.96%+24.9% - DCTH
DELCATH SYSTEMS INC
$10.97M
871,460 sh5.74%-11.1% - MIST
MILESTONE PHARMACEUTICALS
$9.96M
7.43M sh5.21%+80.4% - CMPS
COMPASS PATHWAYS PLC
$8.11M
573,086 sh4.24%-22.8% - KYTX
KYVERNA THERAPEUTICS INC
$7.87M
883,198 sh4.12%+37.0% - ARTV
ARTIVA BIOTHERAPEUTICS IN
$6.76M
696,436 sh3.54%+375.8% - ABEO
ABEONA THERAPEUTICS INC
$6.08M
983,070 sh3.18%-26.1% - AQST
AQUESTIVE THERAPEUTICS IN
$6M
1.44M sh3.14%+102.9% - PALI
PALISADE BIO INC
$5.4M
2.58M sh2.82%+131.6% - IMUX
IMMUNIC INC
$5M
325,022 sh2.61%+38.6% - IVA
INVENTIVA SA - ADR
$4.84M
1.28M sh2.53%+76.8% - SABS
SAB BIOTHERAPEUTICS INC
$4.2M
1.08M sh2.20%+6.3% - OBIO
ORCHESTRA BIOMED HOLDINGS
$3.87M
896,701 sh2.02%+0.0% - CLDX
CELLDEX THERAPEUTICS INC
$3.86M
103,695 sh2.02%-21.1% - ZVRA
ZEVRA THERAPEUTICS INC
$3.64M
253,544 sh1.90%-10.2% - OCUL
OCULAR THERAPEUTIX INC
$3.52M
357,966 sh1.84%-6.4% - FDMT
4D MOLECULAR THERAPEUTICS IN
$3.36M
252,654 sh1.76%-33.6% - OVID
OVID THERAPEUTICS INC
$3M
1.12M sh1.57%+21.1% - EYPT
EYEPOINT INC
$2.74M
191,745 sh1.43%-11.2% - UPB
UPSTREAM BIO INC
$2.42M
350,389 sh1.27%+2.5% - SCYX
SCYNEXIS INC
$2.21M
543,478 sh1.16%New - SLN
SILENCE THERAPEUTICS PLC
$2.11M
191,733 sh1.10%New - LONA
LEONABIO INC
$1.37M
149,279 sh0.72%+0.0% - MAZE
MAZE THERAPEUTICS INC
$1.31M
43,798 sh0.68%+0.0% - CRVS
CORVUS PHARMACEUTICALS INC
$1.05M
70,380 sh0.55%-18.0% - SGMT
SAGIMET BIOSCIENCES INC-A
$973K
125,878 sh0.51%New
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 PAGP PLAINS GP HOLDINGS LP-CL | 1.27M | $30.88M | +0.0% | 16.16% | Q2 2026 |
 ACHV ACHIEVE LIFE SCIENCES INC | 4.03M | $26.34M | +6.5% | 13.79% | Q2 2026 |
 CORT CORCEPT THERAPEUTICS INC | 136,499 | $11.87M | -7.7% | 6.21% | Q2 2026 |
 PHAT PHATHOM PHARMACEUTICALS I | 1.05M | $11.4M | +24.9% | 5.96% | Q2 2026 |
 DCTH DELCATH SYSTEMS INC | 871,460 | $10.97M | -11.1% | 5.74% | Q2 2026 |
 MIST MILESTONE PHARMACEUTICALS | 7.43M | $9.96M | +80.4% | 5.21% | Q2 2026 |
 CMPS COMPASS PATHWAYS PLC | 573,086 | $8.11M | -22.8% | 4.24% | Q2 2026 |
 KYTX KYVERNA THERAPEUTICS INC | 883,198 | $7.87M | +37.0% | 4.12% | Q2 2026 |
 ARTV ARTIVA BIOTHERAPEUTICS IN | 696,436 | $6.76M | +375.8% | 3.54% | Q2 2026 |
 ABEO ABEONA THERAPEUTICS INC | 983,070 | $6.08M | -26.1% | 3.18% | Q2 2026 |
 AQST AQUESTIVE THERAPEUTICS IN | 1.44M | $6M | +102.9% | 3.14% | Q2 2026 |
 PALI PALISADE BIO INC | 2.58M | $5.4M | +131.6% | 2.82% | Q2 2026 |
 IMUX IMMUNIC INC | 325,022 | $5M | +38.6% | 2.61% | Q2 2026 |
 IVA INVENTIVA SA - ADR | 1.28M | $4.84M | +76.8% | 2.53% | Q2 2026 |
 SABS SAB BIOTHERAPEUTICS INC | 1.08M | $4.2M | +6.3% | 2.20% | Q2 2026 |
 OBIO ORCHESTRA BIOMED HOLDINGS | 896,701 | $3.87M | +0.0% | 2.02% | Q2 2026 |
 CLDX CELLDEX THERAPEUTICS INC | 103,695 | $3.86M | -21.1% | 2.02% | Q2 2026 |
 ZVRA ZEVRA THERAPEUTICS INC | 253,544 | $3.64M | -10.2% | 1.90% | Q2 2026 |
 OCUL OCULAR THERAPEUTIX INC | 357,966 | $3.52M | -6.4% | 1.84% | Q2 2026 |
 FDMT 4D MOLECULAR THERAPEUTICS IN | 252,654 | $3.36M | -33.6% | 1.76% | Q2 2026 |
 OVID OVID THERAPEUTICS INC | 1.12M | $3M | +21.1% | 1.57% | Q2 2026 |
 EYPT EYEPOINT INC | 191,745 | $2.74M | -11.2% | 1.43% | Q2 2026 |
 UPB UPSTREAM BIO INC | 350,389 | $2.42M | +2.5% | 1.27% | Q2 2026 |
 SCYX SCYNEXIS INC | 543,478 | $2.21M | New | 1.16% | Q2 2026 |
 SLN SILENCE THERAPEUTICS PLC | 191,733 | $2.11M | New | 1.10% | Q2 2026 |
 LONA LEONABIO INC | 149,279 | $1.37M | +0.0% | 0.72% | Q2 2026 |
 MAZE MAZE THERAPEUTICS INC | 43,798 | $1.31M | +0.0% | 0.68% | Q2 2026 |
 CRVS CORVUS PHARMACEUTICALS INC | 70,380 | $1.05M | -18.0% | 0.55% | Q2 2026 |
 SGMT SAGIMET BIOSCIENCES INC-A | 125,878 | $973K | New | 0.51% | Q2 2026 |
1-29 of 29 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Propel Bio Management, LLC
Propel Bio Management, LLC is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1969764). Signal8 holds 17 13F filings from it. Its SEC filings list California as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 13, 2026. That report lists 29 securities, not counting options, down from 38 in Q1 2026.
Its five largest reported positions, in order, are PLAINS GP HOLDINGS LP-CL (PAGP), ACHIEVE LIFE SCIENCES INC (ACHV), CORCEPT THERAPEUTICS INC (CORT), PHATHOM PHARMACEUTICALS I (PHAT) and DELCATH SYSTEMS INC (DCTH). The next five are MILESTONE PHARMACEUTICALS (MIST), COMPASS PATHWAYS PLC (CMPS), KYVERNA THERAPEUTICS INC (KYTX), ARTIVA BIOTHERAPEUTICS IN (ARTV) and ABEONA THERAPEUTICS INC (ABEO).
Recent 13F filings by Propel Bio Management, LLC
- Q2 2026: 13F-HR filed Aug 13, 2026, listing 29 securities.
- Q1 2026: 13F-HR filed May 14, 2026, listing 38 securities.
- Q4 2025: 13F-HR filed Feb 11, 2026, listing 20 securities.
- Q3 2025: 13F-HR filed Nov 12, 2025, listing 16 securities.
- Q2 2025: 13F-HR filed Aug 13, 2025, listing 16 securities.
- Q1 2025: 13F-HR filed May 15, 2025, listing 18 securities.